de Lonlay Pascale, Fournet Jean-Christophe, Touati Guy, Groos Marie-Sylvie, Martin Delphine, Sevin Caroline, Delagne Véronique, Mayaud Christine, Chigot Valérie, Sempoux Christine, Brusset Marie-Claire, Laborde Kathleen, Bellane-Chantelot Christine, Vassault Anne, Rahier Jacques, Junien Claudine, Brunelle Francis, Nihoul-Fékété Claire, Saudubray Jean-Marie, Robert Jean-Jacques
Federation de Pédiatrie, Hôpital Necker-Enfants-Malades, Paris, France.
Eur J Pediatr. 2002 Jan;161(1):37-48. doi: 10.1007/s004310100847.
Hyperinsulinism is a heterogeneous disorder characterised by severe hypoglycaemia due to an inappropriate oversecretion of insulin. In a personal series of 175 patients investigated for hyperinsulinaemic hypoglycaemia over the last 20 years, we review clinical presentations, molecular studies and therapeutic management of hyperinsulinism. There were 98 neonatal-onset patients, including 86 permanent hyperinsulinism and 12 transient forms, 68 with infancy-onset and nine with childhood-onset. Hyperammonaemia was found in 12 out of 69 patients tested, 4 neonates and 8 infants. Neonates were clinically more severely affected than infants. Diagnosis of infancy-onset hyperinsulinism was often delayed because of less profound hypoglycaemia and better tolerance to hypoglycaemia. Neonates required higher rates of i.v. glucose than infants to maintain normal plasma glucose levels (16 mg/kg per min versus 12 mg/kg per min). Only 16% of neonates were diazoxide-sensitive compared to 66% of the infants. Neonates with hyperammonaemia or transient hyperinsulinism were diazoxide-sensitive. Most neonates were pancreatectomised whereas 65% of the infants were treated medically. Among surgically-treated patients, 47% had a focal adenomatous hyperplasia (31 neonates and 13 infants) and 53% a diffuse form of hyperinsulinism (39 neonates and 11 infants). Diazoxide-responsiveness in the focal and diffuse forms did not differ in both neonates and infants; it depended only upon the age of onset of hypoglycaemia. One or two mutations, SUR1 or KIR6.2, were found in 41 of 73 neonates who were investigated and in 13/38 infants using polymerase chain reaction-single strand conformational polymorphism analysis of both genes. Almost all patients with SUR1 (38/41) or KIR6.2 (5/7) mutations were resistant to diazoxide. Ten patients with hyperinsulinism-hyperammonaemia syndrome had a mutation in the glutamate dehydrogenase gene (three neonates and seven infants) after reverse transcriptase-polymerase chain reaction and sequence analysis of cDNA. No mutation was found by polymerase chain reaction-single strand conformational polymorphism in the glucokinase gene. Eight of nine patients with childhood onset hyperinsulinism were treated surgically and histological examination confirmed an adenoma in each case.
the clinical severity of hyperinsulinism varies mainly with age at onset of hypoglycaemia. The heterogeneity of hyperinsulinism has major consequences in terms of therapeutic outcome and genetic counselling.
高胰岛素血症是一种异质性疾病,其特征是由于胰岛素分泌不当导致严重低血糖。在过去20年里,我们对175例因高胰岛素血症性低血糖接受检查的患者进行了个人系列研究,回顾了高胰岛素血症的临床表现、分子研究和治疗管理。有98例新生儿期起病的患者,包括86例永久性高胰岛素血症和12例短暂性高胰岛素血症,68例婴儿期起病,9例儿童期起病。在69例接受检测的患者中,12例发现高氨血症,4例新生儿和8例婴儿。新生儿在临床上比婴儿受影响更严重。婴儿期起病的高胰岛素血症诊断往往延迟,因为低血糖程度较轻且对低血糖耐受性较好。与婴儿相比,新生儿维持正常血糖水平所需的静脉输注葡萄糖速率更高(16毫克/千克每分钟对12毫克/千克每分钟)。只有16%的新生儿对二氮嗪敏感,而婴儿为66%。患有高氨血症或短暂性高胰岛素血症的新生儿对二氮嗪敏感。大多数新生儿接受了胰腺切除术,而65%的婴儿接受了药物治疗。在接受手术治疗的患者中,47%患有局灶性腺瘤样增生(31例新生儿和13例婴儿),53%患有弥漫性高胰岛素血症(39例新生儿和11例婴儿)。局灶性和弥漫性高胰岛素血症对二氮嗪的反应性在新生儿和婴儿中无差异;它仅取决于低血糖起病的年龄。在73例接受调查的新生儿中的41例以及38例婴儿中的13例中,使用聚合酶链反应 - 单链构象多态性分析这两个基因,发现了一个或两个突变,SUR1或KIR6.2。几乎所有携带SUR1(38/41)或KIR6.2(5/7)突变的患者对二氮嗪耐药。在逆转录酶 - 聚合酶链反应和cDNA序列分析后,10例高胰岛素血症 - 高氨血症综合征患者的谷氨酸脱氢酶基因发生突变(3例新生儿和7例婴儿)。通过聚合酶链反应 - 单链构象多态性在葡萄糖激酶基因中未发现突变。9例儿童期起病的高胰岛素血症患者中有8例接受了手术治疗,组织学检查在每个病例中均证实为腺瘤。
高胰岛素血症的临床严重程度主要随低血糖起病年龄而变化。高胰岛素血症的异质性在治疗结果和遗传咨询方面具有重大影响。